Fabio Candotti is a paediatric immunologist with a specialist interest in defining the cellular and molecular bases of primary immunodeficiency diseases, and the development of gene therapy approaches for these disorders. Based at the University of Lausanne in Switzerland since 2014, his research focuses on defining clinical features of immunodeficient disorders and immunological mechanisms leading to disease in affected patients.
He has actively contributed to the discovery of JAK3-deficiency and AK2-deficiency as causes of SCID, and his laboratory has developed viral-mediated gene correction strategies for SCID-X1, ADA-SCID, Wiskott-Aldrich syndrome (WAS) and IL12Rb1 deficiency. Candotti has extensive experience in clinical applications of gene therapy through trials for the treatment of ADA-SCID using retroviral and lentiviral vectors. He is a member of the Executive Committee of the European Society for Immunodeficiencies, a member of the Editorial Board of the Journal of Clinical Immunology and has authored more than 100 peer-reviewed publications, reviews and book chapters in the fields of immunodeficiency and gene therapy.